Conference Reports for NATAP

Conference on Retroviruses and Opportunistic Infections Seattle, Washington March 4-7, 2019 Back

Tweet

Update on Antiretroviral Drugs and Pregnancy Outcome Including Birth Defects       Lynne M. Mofenson MD Senior HIV Technical Advisor Elizabeth Glaser Pediatric AIDS Foundation   WEBCAST: http://www.croiwebcasts.org/console/player/41144?mediaType=slideVideo&&crd_fl=0&ssmsrq=1554561673549&ctms=5000&csmsrq=5061   CROI 2019 March 4-7 Seattle Reported by Jules Levin   at CROI 2019   DOLUTEGRAVIR: ABSENCE OF DEVELOPMENTAL TOXICITY INCLUDING NTDs IN ANIMAL STUDIES - (03/19/19)   NO INCREASE IN BIRTH DEFECTS IN INFANTS EXPOSED TO INTEGRASE INHIBITORS AT CONCEPTION - (03/19/19)   Albano Study - Integrase Inhibitor Exposure and CNS and Neural Tube Defects: Data from the Antiretroviral Pregnancy Registry (APR) - (03/19/19)   Reports of Neural Tube Defects for 8 ARVs in FDA, WHO, EMA and UK Pharmacovigilance Safety Databases - (03/19/19)   Khoo DOLPHIN2 Study - RCT of dolutegravir vs efavirenz-based therapy initiated in late pregnancy: DOLPHIN-2   Evaluation of Neural Tube Defects After Exposure to Raltegravir During Pregnancy   RANDOMIZED TRIAL OF RALTEGRAVIR-ART VS EFAVIRENZ-ART WHEN INITIATED DURING PREGNANCY - webcast: http://www.croiwebcasts.org/console/player/41080?mediaType=slideVideo&&crd_fl=0&ssmsrq=1554560336247&ctms=5000&csmsrq=5059